Corporate Profile

Incyte’s mission is to become one of the leading global oncology companies.

Incyte Corporation is a Wilmington, Delaware-based biopharmaceutical company focused on the discovery, development and commercialization of proprietary therapeutics, primarily for oncology.  For additional information on Incyte, please visit the Company’s website at www.incyte.com.


Recent News More >>
DateTitle 
May 28, 2015Lilly and Incyte Announce Webcast to Discuss Baricitinib Phase III Data
INDIANAPOLIS, May 28, 2015 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) and Incyte Corporation (Nasdaq: INCY) will host a webcast on June 11 to discuss data from the first two pivotal Phase III studies of baricitinib in rheumatoid arthritis. Data from these two trials, RA-BEACON and RA-BUILD, will be presented on June 11 during the Scientific Programme for the EULAR Congress 2015 in Rome, Italy. The webcast will be held from 10:00 to11:00 a.m. Eastern Daylight Time. The live audio webcast... 
Printer Friendly Version
May 27, 2015Incyte Clinical Portfolio to be Featured in 23 Abstract Presentations at the 2015 ASCO and EHA Annual Meetings
Results from ongoing proof-of-concept trial of PI3Kδ inhibitor INCB40093 as monotherapy and in combination with JAK1 inhibitor INCB39110 in B-cell malignancies, including Hodgkin lymphoma Follow-up results from pivotal RESPONSE trial of ruxolitinib in patients with uncontrolled polycythemia vera, showing 83% of patients were still receiving ruxolitinib at a median exposure of 111 weeks WILMINGTON, Del.--(BUSINESS WIR... 
Printer Friendly Version
April 30, 2015Incyte Reports 2015 First-Quarter Financial Results and Updates Shareholders on Key Clinical Programs
$115 million of 2015 first-quarter net product revenues from Jakafi® (ruxolitinib), representing 66 percent growth over the same period last year $25 million milestone received from Novartis related to the approval of Jakavi® (ruxolitinib) for polycythemia vera in Europe; $16 million product royalties from sales of Jakavi, representing 60 percent growth over the same period last year Primary e... 
Printer Friendly Version

2014 Annual Report
2014 Annual Report Download Documentation

2014 10-K

Notice To Readers: Incyte's press releases, presentations and printed remarks are included on this Web site for historical purposes only. The information contained in these documents and webcasts should be considered accurate only as of the date of the relevant document or presentation. This information may change over time; therefore, visitors to this Web site should not assume that the information contained in these documents or presentations remains accurate at a later time. We do not have any current intention, and expressly disclaim any obligation, to supplement, update or revise any of the information in these documents or presentations.


Replication or redistribution of EDGAR Online, Inc. content is expressly prohibited without the prior written consent of EDGAR Online, Inc. EDGAR Online, Inc. shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.